Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia

Aging (Albany NY). 2021 Nov 1;13(21):23895-23912. doi: 10.18632/aging.203663. Epub 2021 Nov 1.

Abstract

The coronavirus disease 2019 (COVID-19) is presently the most pressing public health concern worldwide. Cytokine storm is an important factor leading to death of patients with COVID-19. This study aims to characterize serum cytokines of patients with severe or critical COVID-19. Clinical records were obtained from 149 patients who were tested at the Sino-French New City Branch of Tongji Hospital from 30 January to 30 March 2020. Data regarding the clinical features of the patients was collected and analyzed. Among the 149, 45 (30.2%) of them had severe conditions and 104 (69.8%) of that presented critical symptoms. In the meantime, 80 (53.7%) of that 149 died during hospitalization. Of all, male patients accounted for 94 (69.1%). Compared with patients in severe COVID-19, those who in critical COVID-19 had significantly higher levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, and IL-10. Moreover, the passed-away patients had considerably higher levels of TNF-α, IL-6, IL-8, and IL-10 than those survived from it. Regression analysis revealed that serum TNF-α level was an independent risk factor for the death of patient with severe conditions. Among the proinflammatory cytokines (IL-1β, TNF-α, IL-8, and IL-6) analyzed herein, TNF-α was seen as a risk factor for the death of patients with severe or critical COVID-19. This study suggests that anti-TNF-α treatment allows patients with severe or critical COVID-19 pneumonia to recover.

Keywords: COVID-19; TNF-alpha; cytokine storm; illness severity; mortality.

MeSH terms

  • COVID-19* / diagnosis
  • COVID-19* / immunology
  • COVID-19* / mortality
  • COVID-19* / therapy
  • China / epidemiology
  • Critical Illness* / mortality
  • Critical Illness* / therapy
  • Female
  • Hospital Mortality
  • Humans
  • Immunologic Tests / methods
  • Interleukins / blood*
  • Male
  • Middle Aged
  • Mortality
  • Pneumonia, Viral* / diagnostic imaging
  • Pneumonia, Viral* / etiology
  • Predictive Value of Tests
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index
  • Tomography, X-Ray Computed / methods
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Tumor Necrosis Factor-alpha / blood*

Substances

  • Interleukins
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha